Revenue Ka Toofan, Profit Mein Thoda Fall
So, Epigral ka share aaj 10% se bhi upar chala gaya! Asal mein, company ne Quarterly Revenue ka naya record banaya hai, ₹736.16 crore tak pahunch gaya jo pichhle saal se 17.29% zyada hai. Lekin ek twist hai, profit thoda kam hua hai, lagbhag 6.84% neeche gir kar ₹80.95 crore pe aa gaya. EBITDA bhi thoda 4.96% contraction dikha raha hai, ₹168.01 crore ho gaya hai.
Future Ke Liye Bada Investment Aur Valuation Ka Discount
Company future ke liye full on paisa laga rahi hai! FY26 mein capacity badhane mein ₹394 crore kharch kiye hain. CPVC resin capacity 150,000 TPA aur epichlorohydrin capacity 100,000 TPA tak badha rahe hain. Jabki company ka Return on Equity (ROE) 24.93% hai, iska valuation apne competitors jaise Clean Science (P/E ~35.66x) aur Alkyl Amines (P/E ~42.80x) se kaafi kam hai. Sector ka average P/E 30x-42x ke aas paas hai, jabki Epigral ka TTM P/E sirf ~15.5x hai. Debt-to-equity ratio bhi control mein hai, 0.31 ke aas paas.
Analysts Ko Future Pe Bharosa
Management ka kehna hai ki agar global market stable raha toh demand aage bhi acchi rahegi. Analysts bhi is par kaafi confident hain. Unka kehna hai ki abhi profit margins ki chinta mat karo, expansion plans se future mein zaroor growth hogi. Isliye sab ne mil kar 'Strong Buy' rating di hai aur ₹2,000 ka target price set kiya hai.
